ArticleFuture oncology (London, England)2024

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with

Suzanne George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.